SEC Filings


Form 10-Q
Raptor Pharmaceutical Corp filed this Form 10-Q on 07/15/10
Document Outline
Entire Document (2071.3 KB)
Subdocument 1 - 10-Q - RAPTOR 10-Q 053110
Page 1 - UNITED STATES
Page 2 - RAPTOR PHARMACEUTICAL CORP.
Page 3 - PART I – FINANCIAL INFORMATION
Page 4 - Raptor Pharmaceutical Corp.
Page 5 - N/A
Page 6 - N/A
Page 7 - RAPTOR PHARMACEUTICAL CORP.
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Page 26 - N/A
Page 27 - N/A
Page 28 - Item
Page 29 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Page 30 - Future Activities
Page 31 - Development of DR Cysteamine for the Potential Treatment of Huntington’s Disease or HD
Page 32 - Tezampanel and NGX426 for the Potential Treatment of Migraine and Pain
Page 33 - HepTide
Page 34 - Proceedings of the National Academy of Sciences
Page 35 - Purchase of DR Cysteamine
Page 36 - Fair Value of Financial Instruments
Page 37 - Research and Development
Page 38 - Equity-Based Payments to Non-Employees
Page 39 - Research and Development
Page 40 - Current Status of Major Programs
Page 41 - Liquidity and Capital Resources
Page 42 - N/A
Page 43 - General and Administrative
Page 44 - •
Page 45 - N/A
Page 46 - Off-Balance Sheet Arrangements
Page 47 - Derivatives and Hedging,
Page 48 - Fair Value Measurements and Disclosures (Topic 820): Improving Disclosures about Fair Value Measurem
Page 49 - Changes in Internal Control Over Financial Reporting
Page 50 - •
Page 51 - Even if we are able to develop our drug product candidates, we may not be able to receive regulatory
Page 52 - If we fail to compete successfully with respect to acquisitions, joint venture and other collaborati
Page 53 - •
Page 54 - If we fail to obtain or maintain orphan drug exclusivity for some of our drug product candidates, ou
Page 55 - Companies and universities that have licensed product candidates to us for research, clinical develo
Page 56 - Our success depends on our ability to manage our growth.
Page 57 - We may be required to suspend, repeat or terminate our clinical trials if they do not meet regulator
Page 58 - We may not complete our clinical trials in the time expected, which could delay or prevent the comme
Page 59 - •
Page 60 - N/A
Page 61 - Because we do not intend to pay any cash dividends on our common stock, investors will benefit from
Page 62 - •
Page 63 - We can issue shares of preferred stock that may adversely affect the rights of a stockholder of our
Page 64 - Issuance Date
Page 65 - Item 6. Exhibits
Page 66 - SIGNATURES
Page 67 - Exhibit Index
Page 68 - N/A
Subdocument 2 - EX-31.1 - CEO CERTIFICATION
Page 1 - EXHIBIT 31.1
Page 2 - N/A
Subdocument 3 - EX-31.2 - CFO CERTIFICATION
Page 1 - EXHIBIT 31.2
Page 2 - N/A
Subdocument 4 - EX-32.1 - CEO AND CFO CERTIFICATIONS
Page 1 - Exhibit 32.1
Page 2 - N/A